Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.3420
+0.00972.92%
Pre-market: 0.3379-0.0041-1.20%06:12 EDT
Volume:2.00M
Turnover:679.73K
Market Cap:6.46M
PE:-0.09
High:0.3609
Open:0.3321
Low:0.3229
Close:0.3323
52wk High:14.80
52wk Low:0.3229
Shares:18.90M
Float Shares:17.23M
Volume Ratio:1.14
T/O Rate:11.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.20
PE(LYR):-0.08

Loading ...

Volitionrx Held Annual Shareholder Meeting; 4,261,161 Shares Represented by Proxy or in Person

Reuters
·
Jul 22

Volitionrx Posts Corporate Deck Outlining Nu.q Licensing Strategy Across Cancer, Sepsis and Veterinary Testing

Reuters
·
Jul 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

TIPRANKS
·
Jul 08

Volitionrx Announces Availability of New Press Release

Reuters
·
Jul 07

Volitionrx Announces Data Showing the Prognostic Value of Its Nu.q® Cancer Test

THOMSON REUTERS
·
Jul 07

VolitionRx issues 333,332 shares to Lind to satisfy $416,666 note payment obligation

Reuters
·
Jun 19

VolitionRX Price Target Announced at $4.00/Share by Maxim Group

Dow Jones
·
Jun 19

VolitionRx Collaborates With Japan's Sysmex for Optimization on Platform

MT Newswires Live
·
Jun 17

VolitionRx partners with Sysmex to optimize Nu.Q NETs H3.1 assay on Sysmex platform

Reuters
·
Jun 17

VolitionRX Announces Collaboration With Sysmex

THOMSON REUTERS
·
Jun 17

VolitionRx prices public offering to raise USD 4.6 million upfront

Reuters
·
Jun 10

VolitionRX Announces Pricing of $4.6 Million Public Offering

THOMSON REUTERS
·
Jun 08

VolitionRx files patent covering Nu.Q technology for Ebola triage

TIPRANKS
·
Jun 03

VolitionRx files patent application for Nu.Q NETs Ebola triage test

Reuters
·
Jun 03

VolitionRX - Seeks Partners for Field Trials and Deployment of Lft Prototypes in Outbreak Zones

THOMSON REUTERS
·
Jun 03

VolitionRX Files New Patent Protecting Its Nu.q® Nets Test for Ebola Triage and Treatment Monitoring

THOMSON REUTERS
·
Jun 03

VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing

Reuters
·
May 28

VolitionRx posts $1 million Q1 revenue, up 300% year over year

Reuters
·
May 27

VolitionRx submits peer-reviewed study of Nu.Q Vet feline lymphoma blood test, eyes $5 million milestone

Reuters
·
May 27

VolitionRx waives Lind note covenant breach, triggers 10% step-up charge

Reuters
·
May 23